Bicycle Therapeutics plc (BCYC)
BCYCNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$3.77
+0.1550 (+4.29%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $264.25m
- P/E
- –
- EPS, last 4 quarters
- $-2.03
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.33 to $7.83
- Average volume
- 441.1k
- Previous close
- $3.62
Analysts
2 coveringHold0 buy, 2 hold, 0 sell
Targets a year out average $5.00, +32.6% from here
Earnings
next estimate $-0.3600Next report
Dec 2025
+71.0%
Mar 2026
-67.3%
Jun 2026
-94.6%
Sep 2026
+50.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $47.95m | $887.0k | $629.0k | $34.06m |
| Gross profit | $47.95m | $887.0k | $629.0k | $34.06m |
| Operating income | -$24.71m | -$65.48m | -$54.56m | -$13.48m |
| Net income | -$20.15m | -$60.83m | -$50.33m | -$10.48m |
Last four quarters: revenue $83.53m, margin -169.8%, free cash flow -$177.04m
News
8 latest- Bicycle Therapeutics Reports Q3 Results; Nuzefatide Updates Expected In 2027 RTTNews · Oct 29, 2026
- Bicycle Therapeutics plc Reports Third Quarter 2026 Financial ResultsFintel · Oct 29, 2026
- Bicycle Therapeutics Q2 Loss Narrows; Advances Cancer Pipeline RTTNews · Jul 31, 2026
- Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?Zacks · Jul 3, 2026
- Kymera Appoints Felix Baker As Board Chairman, Succeeds Bruce Booth RTTNews · Jun 25, 2026
- Bicycle Therapeutics Highlights On Nuzefatide Pevedotin And EphA2 Pipeline At AACR Meet 2026 RTTNews · Apr 21, 2026
- Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to TradeZacks · Apr 16, 2026
- After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)Zacks · Mar 24, 2026
The company
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- bicycletherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.